Clinical trial • Phase II • Gastroenterology
MIRIKIZUMAB for Ulcerative colitis
Phase II trial of MIRIKIZUMAB for Ulcerative colitis.
Overview
- Trial Therapeutic Area
- Gastroenterology
- Trial Disease
- Ulcerative colitis
- Trial Stage
- Phase II
- Drug Modality
- Monoclonal antibody | Small molecule
Key dates
- Initial CTIS Submission Date
- 24-11-2025
- First CTIS Authorization Date
- 18-03-2026
Trial design
Randomised, mirikizumab monotherapy (active comparator); placebos (placebo to mirikizumab; placebo to match ly) are used. dose and schedule not specified in the ctis record.-controlled Phase II trial in Austria, Germany, Hungary and others.
- Randomised
- Yes
- Comparator
- Mirikizumab monotherapy (active comparator); placebos (Placebo to Mirikizumab; Placebo to match LY) are used. Dose and schedule not specified in the CTIS record.
- Target Sample Size
- 177
Eligibility
Recruits 177 adults.
Inclusion criteria
- {"criterion_text":"- Have had an established diagnosis of UC of ≥3 months in before baseline"}
- {"criterion_text":"- Have moderately to severely active UC"}
- {"criterion_text":"- Have evidence of UC extending proximal to the rectum"}
- {"criterion_text":"- Participants with greater than 8 years of UC symptoms have documented evidence of having had a surveillance colonoscopy within 1 year, or according to local country or regional medical guidelines, to evaluate for polyps, dysplasia, or malignancy, prior to randomization."}
- {"criterion_text":"- Are up-to-date on colorectal cancer surveillance"}
- {"criterion_text":"- Have an inadequate response to, loss of response to, or intolerance to Conventional therapy, Immunomodulators, Advanced therapy"}
Exclusion criteria
- {"criterion_text":"- Have a current diagnosis of Crohn’s disease, IBD unclassified or primary sclerosing cholangitis"}
- {"criterion_text":"- Have an inherited immunodeficiency syndrome or known monogenic cause of UC-like colonic inflammation."}
- {"criterion_text":"- Have had or will need bowel resection or intestinal or intra-abdominal surgery"}
- {"criterion_text":"- Are likely to require surgery for the treatment of UC during the study"}
- {"criterion_text":"- Have evidence of toxic megacolon, intra-abdominal abscess, or stricture or stenosis within small bowel or colon that cannot be traversed by a colonoscope or that are symptomatic."}
Endpoints
Primary endpoints
- {"endpoint_text":"- The proportion of participants who achieve clinical remission with mMS at Week 12","definition_or_measurement_approach":""}
Recruitment
- Digital Remote Recruitment
- Yes
- Planned Sample Size
- 177
- Recruitment Window Months
- 35
- Consent Approach
- Informed consent obtained from adult participants. Site-specific Subject Information Sheet (SIS) and Informed Consent Forms (ICF) are provided, with country/language-specific versions available (documents include language/local variants: German (de-AUT/DE), Spanish, Polish (PL), Dutch (NL), Hungarian (HU), Italian (IT), Romanian (RO) and English). Optional consent addendum for genetic research is included (document 'L1_SIS and ICF_Addendum ICF_Optional Genetic'). Consent is provided by the participant (no paediatric/assent provisions are specified in the record).
Methods
- Digital campaigns: social media video scripts, search ads, digital ad visuals and copy, digital screener and digital recruitment ads (documents: titles include 'Digital Campaign', 'Digital_Ad_Master', 'Social_Media_Video_Script', 'Digital_Ad_Visuals_Master'). Country-localised digital materials are present (e.g. Italy, Netherlands, Poland, Hungary references in document titles).
- Printed materials: Flyers, Posters, Brochures (K2_Recruitment material_Flyer/Master, Poster, Brochure) targeted to patients with moderately to severely active ulcerative colitis.
- Healthcare professional recruitment: Doctor-to-patient letters and doctor-to-doctor referral letters (documents titled 'Letter-Doctor-to-Patient', 'Doctor to Doctor referral letter').
- Patient-facing materials: Patient cards / Study participant contact cards and brochures provided at sites.
- Country-localised recruitment packages: K1/K2 recruitment arrangements and country-specific packs (files labelled with country codes or language indicators: e.g. _HU_, _NL_, _PL_, de-AUT, etc.).
Geography
- Total Number Of Sites
- 45
- Total Number Of Participants
- 75
Austria
- Earliest CTIS Part Ii Submission Date
- 06-03-2026
- Latest Decision Or Authorization Date
- 22-03-2026
- Processing Time Days
- 16
- Number Of Sites
- 2
- Number Of Participants
- 5
Sites
- Site Name
- Medical University Of Vienna
- Department Name
- Abteilung für Gastroenterologie und Hepatologie Loc. 1
- Principal Investigator Name
- Walter Reinisch
- Principal Investigator Email
- walter.reinisch@meduniwien.ac.at
- Contact Person Name
- Walter Reinisch
- Contact Person Email
- walter.reinisch@meduniwien.ac.at
- Site Name
- Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH
- Department Name
- Innere Medizin I Loc. 1
- Principal Investigator Name
- Sonja Heeren
- Principal Investigator Email
- s.heeren@salk.at
- Contact Person Name
- Sonja Heeren
- Contact Person Email
- s.heeren@salk.at
Germany
- Earliest CTIS Part Ii Submission Date
- 18-02-2026
- Latest Decision Or Authorization Date
- 18-03-2026
- Processing Time Days
- 28
- Number Of Sites
- 4
- Number Of Participants
- 5
Sites
- Site Name
- Universitaetsklinikum Regensburg AöR
- Department Name
- Department of Internal Medicine I
- Principal Investigator Name
- Arne Kandulski
- Principal Investigator Email
- arne.kandulski@ukr.de
- Contact Person Name
- Arne Kandulski
- Contact Person Email
- arne.kandulski@ukr.de
- Site Name
- Studienzentrum MVZ Dachau
- Principal Investigator Name
- Wilfred Landry
- Principal Investigator Email
- landry@dachau-med.de
- Contact Person Name
- Wilfred Landry
- Contact Person Email
- landry@dachau-med.de
- Site Name
- Charité Universitaetsmedizin Berlin - Campus Mitte
- Department Name
- Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie CCM/CVK
- Principal Investigator Name
- Christoph Jochum
- Principal Investigator Email
- christoph.jochum@charite.de
- Contact Person Name
- Christoph Jochum
- Contact Person Email
- christoph.jochum@charite.de
- Site Name
- Universitaetsklinikum Ulm AöR
- Department Name
- Department of Internal Medicine I
- Principal Investigator Name
- Jochen Klaus
- Principal Investigator Email
- jochen.klaus@uniklinik-ulm.de
- Contact Person Name
- Jochen Klaus
- Contact Person Email
- jochen.klaus@uniklinik-ulm.de
Hungary
- Earliest CTIS Part Ii Submission Date
- 29-01-2026
- Latest Decision Or Authorization Date
- 27-03-2026
- Processing Time Days
- 57
- Number Of Sites
- 8
- Number Of Participants
- 14
Sites
- Site Name
- Bekes Varmegyei Koezponti Korhaz
- Department Name
- 4. Belgyógyászat Gasztroenterológia
- Principal Investigator Name
- Márta Varga
- Principal Investigator Email
- drvargamarta@gmail.com
- Contact Person Name
- Márta Varga
- Contact Person Email
- drvargamarta@gmail.com
- Site Name
- Semmelweis University
- Department Name
- Belgyogyaszati es Hematologai Klinika
- Principal Investigator Name
- Zsolt Tulassay
- Principal Investigator Email
- tulassay.zsolt@semmelweis.hu
- Contact Person Name
- Zsolt Tulassay
- Contact Person Email
- tulassay.zsolt@semmelweis.hu
- Site Name
- Clinexpert Gyoengyoes Kft.
- Principal Investigator Name
- Gyula Horvát
- Principal Investigator Email
- horvatgyula@gmail.com
- Contact Person Name
- Gyula Horvát
- Contact Person Email
- horvatgyula@gmail.com
- Site Name
- Javorszky Oedoen Korhaz
- Department Name
- Gastroenterology
- Principal Investigator Name
- Tibor Szalóki
- Principal Investigator Email
- szalokitdr@javorszky.hu
- Contact Person Name
- Tibor Szalóki
- Contact Person Email
- szalokitdr@javorszky.hu
- Site Name
- Komarom-Esztergom Varmegyei Szent Borbala Korhaz
- Department Name
- Gastroenterology
- Principal Investigator Name
- András Káfony
- Principal Investigator Email
- kafony@gmail.com
- Contact Person Name
- András Káfony
- Contact Person Email
- kafony@gmail.com
- Site Name
- Pannonia Maganorvosi Centrum Kft.
- Principal Investigator Name
- Róbert Schnabel
- Principal Investigator Email
- schnabelrobert@hotmail.com
- Contact Person Name
- Róbert Schnabel
- Contact Person Email
- schnabelrobert@hotmail.com
- Site Name
- Obudai Egeszseguegyi Centrum Kft.
- Principal Investigator Name
- Gábor Tamás Tóth
- Principal Investigator Email
- medicatorbt@gmail.com
- Contact Person Name
- Gábor Tamás Tóth
- Contact Person Email
- medicatorbt@gmail.com
- Site Name
- Clinexpert Gyoengyoes Kft. (second listing)
Italy
- Earliest CTIS Part Ii Submission Date
- 26-02-2026
- Latest Decision Or Authorization Date
- 24-03-2026
- Processing Time Days
- 26
- Number Of Sites
- 5
- Number Of Participants
- 8
Sites
- Site Name
- ASST Grande Ospedale Metropolitano Niguarda
- Department Name
- SC Epatologia e Gastroenterologia
- Principal Investigator Name
- Marcello Vangeli
- Principal Investigator Email
- marcello.vangeli@ospedaleniguarda.it
- Contact Person Name
- Marcello Vangeli
- Contact Person Email
- marcello.vangeli@ospedaleniguarda.it
- Site Name
- Humanitas Mirasole S.p.A.
- Department Name
- Gastroenterology and Gastrointestinal Endoscopy
- Principal Investigator Name
- Alessandro Armuzzi
- Principal Investigator Email
- clinicaltrialsibd@humanitas.it
- Contact Person Name
- Alessandro Armuzzi
- Contact Person Email
- clinicaltrialsibd@humanitas.it
- Site Name
- Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
- Department Name
- Gastroenterology and Endoscopy
- Principal Investigator Name
- Flavio Caprioli
- Principal Investigator Email
- flavio.caprioli@unimi.it
- Contact Person Name
- Flavio Caprioli
- Contact Person Email
- flavio.caprioli@unimi.it
- Site Name
- Ospedale San Raffaele S.r.l.
- Department Name
- Gastroenterology and Gastrointestinal Endoscopy
- Principal Investigator Name
- Silvio Danese
- Principal Investigator Email
- ibd.trials@hsr.it
- Contact Person Name
- Silvio Danese
- Contact Person Email
- ibd.trials@hsr.it
- Site Name
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Department Name
- Dipartimento di Medicina Interna e Gastroenterologia
- Principal Investigator Name
- Franco Scaldaferri
- Principal Investigator Email
- franco.scaldaferri@policlinicogemelli.it
- Contact Person Name
- Franco Scaldaferri
- Contact Person Email
- franco.scaldaferri@policlinicogemelli.it
Romania
- Earliest CTIS Part Ii Submission Date
- 12-02-2026
- Latest Decision Or Authorization Date
- 23-03-2026
- Processing Time Days
- 39
- Number Of Sites
- 7
- Number Of Participants
- 7
Sites
- Site Name
- Memorial Healthcare International S.R.L.
- Department Name
- Gastroenterology
- Principal Investigator Name
- Ion-Eugeniu Craciun
- Principal Investigator Email
- eugencraciun@yahoo.com
- Contact Person Name
- Ion-Eugeniu Craciun
- Contact Person Email
- eugencraciun@yahoo.com
- Site Name
- Spital Judetean De Urgenta Satu Mare
- Department Name
- Gastroenterology
- Principal Investigator Name
- Bogdan Pintea
- Principal Investigator Email
- Dr.bogdan.pintea@gmail.com
- Contact Person Name
- Bogdan Pintea
- Contact Person Email
- Dr.bogdan.pintea@gmail.com
- Site Name
- Delta Health Care S.R.L.
- Department Name
- Gastroenterology
- Principal Investigator Name
- Camelia Chioncel
- Principal Investigator Email
- cameliachioncel@yahoo.com
- Contact Person Name
- Camelia Chioncel
- Contact Person Email
- cameliachioncel@yahoo.com
- Site Name
- Spitalul Clinic Judetean De Urgenta Sfantul Apostol Andrei Constanta
- Department Name
- Gastroenterology
- Principal Investigator Name
- Eugen Dumitru
- Principal Investigator Email
- eugen.dumitru@yahoo.com
- Contact Person Name
- Eugen Dumitru
- Contact Person Email
- eugen.dumitru@yahoo.com
- Site Name
- Centrul De Gastroenterologie Dr. Goldis S.R.L.
- Department Name
- Gastroenterology
- Principal Investigator Name
- Eugen Goldis
- Principal Investigator Email
- goldisadi@yahoo.com
- Contact Person Name
- Eugen Goldis
- Contact Person Email
- goldisadi@yahoo.com
- Site Name
- Spitalul Clinic Colentina Bucuresti
- Department Name
- Gastroenterology
- Principal Investigator Name
- Bogdan Mateescu
- Principal Investigator Email
- bogmateescu@gmail.com
- Contact Person Name
- Bogdan Mateescu
- Contact Person Email
- bogmateescu@gmail.com
- Site Name
- Delta Health Care S.R.L. (additional listing)
Spain
- Earliest CTIS Part Ii Submission Date
- 17-12-2025
- Latest Decision Or Authorization Date
- 20-03-2026
- Processing Time Days
- 93
- Number Of Sites
- 5
- Number Of Participants
- 4
Sites
- Site Name
- Centro Medico Teknon-Grupo Quironsalud
- Department Name
- Gastroenterología
- Principal Investigator Name
- Miquel Sans Cuffi
- Principal Investigator Email
- miquelsanscuffi@gmail.com
- Contact Person Name
- Miquel Sans Cuffi
- Contact Person Email
- miquelsanscuffi@gmail.com
- Site Name
- Hospital Universitario Nuestra Senora De Candelaria
- Department Name
- Gastroenterología
- Principal Investigator Name
- Alejandro Hernandez Camba
- Principal Investigator Email
- dr.alejandrohc@gmail.com
- Contact Person Name
- Alejandro Hernandez Camba
- Contact Person Email
- dr.alejandrohc@gmail.com
- Site Name
- Hospital Universitario De Cabuenes
- Department Name
- Digestivo
- Principal Investigator Name
- Pilar Varela Trastoy
- Principal Investigator Email
- trastoy@hotmail.com
- Contact Person Name
- Pilar Varela Trastoy
- Contact Person Email
- trastoy@hotmail.com
- Site Name
- Hospital Universitario De Fuenlabrada
- Department Name
- Digestivo
- Principal Investigator Name
- Fernando Bermejo San José
- Principal Investigator Email
- fernando.bermejo@salud.madrid.org
- Contact Person Name
- Fernando Bermejo San José
- Contact Person Email
- fernando.bermejo@salud.madrid.org
- Site Name
- Hospital Universitario La Paz
- Department Name
- Unidad de Enfermedad Inflamatoria Intestinal
- Principal Investigator Name
- Maria Dolores Martin Arranz
- Principal Investigator Email
- martinarranz.lapaz@gmail.com
- Contact Person Name
- Maria Dolores Martin Arranz
- Contact Person Email
- martinarranz.lapaz@gmail.com
Netherlands
- Earliest CTIS Part Ii Submission Date
- 23-03-2026
- Latest Decision Or Authorization Date
- 30-03-2026
- Processing Time Days
- 7
- Number Of Sites
- 2
- Number Of Participants
- 4
Sites
- Site Name
- Radboud universitair medisch centrum Stichting
- Department Name
- Gastroenterology
- Principal Investigator Name
- Marjolijn Duijvestein
- Principal Investigator Email
- marjolijn.duijvestein@radboudumc.nl
- Contact Person Name
- Marjolijn Duijvestein
- Contact Person Email
- marjolijn.duijvestein@radboudumc.nl
- Site Name
- Stichting Elisabeth-Tweesteden Ziekenhuis
- Department Name
- Department of Gastroenterology and Hepatology
- Principal Investigator Name
- Robert Laheij
- Principal Investigator Email
- r.laheij@etz.nl
- Contact Person Name
- Robert Laheij
- Contact Person Email
- r.laheij@etz.nl
Poland
- Earliest CTIS Part Ii Submission Date
- 24-02-2026
- Latest Decision Or Authorization Date
- 11-05-2026
- Processing Time Days
- 76
- Number Of Sites
- 9
- Number Of Participants
- 20
Sites
- Site Name
- Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o.
- Department Name
- TBC
- Principal Investigator Name
- Beata Gawdis-Wojnarska
- Principal Investigator Email
- gawdis@twojaprzychodnia.com
- Contact Person Name
- Beata Gawdis-Wojnarska
- Contact Person Email
- gawdis@twojaprzychodnia.com
- Site Name
- Uniwersyteckie Centrum Stomatologii I Medycyny Specjalistycznej Sp. z o.o.
- Department Name
- TBC
- Principal Investigator Name
- Piotr Eder
- Principal Investigator Email
- piotreder@ump.edu.pl
- Contact Person Name
- Piotr Eder
- Contact Person Email
- piotreder@ump.edu.pl
- Site Name
- Pratia S.A.
- Department Name
- TBC
- Principal Investigator Name
- Magdalena Andrzejewska
- Principal Investigator Email
- magdalena.andrzejewska@pratia.com
- Contact Person Name
- Magdalena Andrzejewska
- Contact Person Email
- magdalena.andrzejewska@pratia.com
- Site Name
- Gyncentrum Sp. z o.o.
- Department Name
- TBC
- Principal Investigator Name
- Marek Olakowski
- Principal Investigator Email
- m.olakowski@holsaclinical.com
- Contact Person Name
- Marek Olakowski
- Contact Person Email
- m.olakowski@holsaclinical.com
- Site Name
- Etg Zamosc Sp. z o.o.
- Department Name
- TBC
- Principal Investigator Name
- Katarzyna Wójcik
- Principal Investigator Email
- k.wojcik@etg-network.com
- Contact Person Name
- Katarzyna Wójcik
- Contact Person Email
- k.wojcik@etg-network.com
- Site Name
- Sonomed Sp. z o.o.
- Department Name
- TBC
- Principal Investigator Name
- Anna Wiechowska-Kozłowska
- Principal Investigator Email
- anna.kozlowska@sonomedszczecin.pl
- Contact Person Name
- Anna Wiechowska-Kozłowska
- Contact Person Email
- anna.kozlowska@sonomedszczecin.pl
- Site Name
- Medical Network Sp. z o.o.
- Department Name
- TBC
- Principal Investigator Name
- Jaroslaw Kierkuś
- Principal Investigator Email
- j.kierkus@med-net.pl
- Contact Person Name
- Jaroslaw Kierkuś
- Contact Person Email
- j.kierkus@med-net.pl
- Site Name
- Irmed Klimkiewicz Rudziewicz-Kowalska sp. j.
- Department Name
- TBC
- Principal Investigator Name
- Katarzyna Ostrowska
- Principal Investigator Email
- gastrolog1@ir-med.pl
- Contact Person Name
- Katarzyna Ostrowska
- Contact Person Email
- gastrolog1@ir-med.pl
- Site Name
- Wsd Medi Clinical Sp. z o.o.
- Department Name
- TBC
- Principal Investigator Name
- Michał Krogulecki
- Principal Investigator Email
- michalkrogulecki@medi-clinical.pl
- Contact Person Name
- Michał Krogulecki
- Contact Person Email
- michalkrogulecki@medi-clinical.pl
Denmark
- Earliest CTIS Part Ii Submission Date
- 20-03-2026
- Latest Decision Or Authorization Date
- 24-04-2026
- Processing Time Days
- 35
- Number Of Sites
- 3
- Number Of Participants
- 8
Sites
- Site Name
- Odense University Hospital
- Department Name
- Medical Gastroenterology
- Principal Investigator Name
- Mark Ainsworth
- Principal Investigator Email
- mark.ainsworth@rsyd.dk
- Contact Person Name
- Mark Ainsworth
- Contact Person Email
- mark.ainsworth@rsyd.dk
- Site Name
- Herlev and Gentofte Hospital
- Department Name
- Gastroenterology and Hepatology
- Principal Investigator Name
- Jakob Seidelin
- Principal Investigator Email
- jakob.benedict.seidelin@regionh.dk
- Contact Person Name
- Jakob Seidelin
- Contact Person Email
- jakob.benedict.seidelin@regionh.dk
Sponsor
Primary sponsor
- Full Name
- Eli Lilly & Co.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Contract research organisations
- Name
- Alimentiv Inc.
- Responsibilities
- 4
- Name
- Icon Development Solutions LLC
- Responsibilities
- 4
- Name
- Bioagilytix Labs LLC
- Responsibilities
- 4
- Name
- Q2 Solutions LLC
- Responsibilities
- 4
Third parties
- {"country":"United Kingdom","full_name":"IQVIA Limited","duties_or_roles":"1","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Veeva Systems Inc.","duties_or_roles":"6","organisation_type":"Non-Pharmaceutical company"}
- {"country":"Canada","full_name":"Alimentiv Inc.","duties_or_roles":"4","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"The Hibbert Co.","duties_or_roles":"15: Procurement and shipping of appreciation items, printing and shipping of R&R materials","organisation_type":"Non-Pharmaceutical company"}
- {"country":"United States","full_name":"Clinical Trial Media Inc.","duties_or_roles":"2","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Icon Development Solutions LLC","duties_or_roles":"4","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Bioagilytix Labs LLC","duties_or_roles":"4","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Florence","duties_or_roles":"15: Site document management","organisation_type":"Health care"}
- {"country":"United States","full_name":"Fisher Clinical Services, by Thermo Fisher Scientific","duties_or_roles":"15: Clinical Trial Material Warehousing and Distribution Operations","organisation_type":"Health care"}
- {"country":"United States","full_name":"Propharma Group LLC","duties_or_roles":"2","organisation_type":"Pharmaceutical company"}
- {"country":"United Kingdom","full_name":"Yprime","duties_or_roles":"7","organisation_type":"Health care"}
- {"country":"United States","full_name":"Greenphire LLC","duties_or_roles":"15: Patient reimboursement and travel services","organisation_type":"Non-Pharmaceutical company"}
- {"country":"United States","full_name":"OneStudy Team","duties_or_roles":"2","organisation_type":"Health care"}
- {"country":"United States","full_name":"RWS Life Sciences Inc.","duties_or_roles":"6","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Q2 Solutions LLC","duties_or_roles":"4","organisation_type":"Laboratory/Research/Testing facility"}
- {"country":"United States","full_name":"Q2 Solutions (alternate listing)","duties_or_roles":"4","organisation_type":"Industry"}
- {"country":"United States","full_name":"Cleveland Clinic Foundation","duties_or_roles":"15: Adjudication","organisation_type":"Hospital/Clinic/Other health care facility"}
Investigational products
- Investigational Product Name
- Mirikizumab
- Active Substance
- MIRIKIZUMAB
- Modality
- Monoclonal antibody
- Routes Of Administration
- SUBCUTANEOUS USE | INTRAVENOUS
- Route
- SUBCUTANEOUS / INTRAVENOUS
- Authorisation Status
- Authorised
- Maximum Dose
- 200 mg (subcutaneous) / 300 mg (intravenous)
- Investigational Product Name
- LY4268989 (MORF-057)
- Active Substance
- (S)-3-((S)-2-(5-(2-(DIMETHYLAMINO)ETHYL)-2 OXO-4-(TRIFLUOROMETHYL)PYRIDIN-1(2H)-YL)-4-METHYLPENTANAMIDO)-3-(4-FLUORO-2',4',5,6'-TETRAMETHYL-[1,1'-BIPHENYL]-3-YL)PROPANOIC ACID (synonyms: MORF-057, LY4268989)
- Modality
- Small molecule
- Routes Of Administration
- ORAL
- Route
- ORAL
- Authorisation Status
- Authorised
- Investigational Product Name
- Placebo to Mirikizumab
- Modality
- Other
- Investigational Product Name
- Placebo to match LY
- Modality
- Other
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.